Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

  • Abstract
  • Literature Map
  • Similar Papers
Abstract
Translate article icon Translate Article Star icon
Take notes icon Take Notes

Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Similar Papers
  • Research Article
  • 10.1182/blood-2025-7256
Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.
  • Nov 3, 2025
  • Blood
  • Chenwen Wang + 5 more

Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.

  • Abstract
  • Cite Count Icon 6
  • 10.1182/blood-2019-131499
Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma
  • Nov 13, 2019
  • Blood
  • Chelsea C Pinnix + 20 more

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  • Abstract
  • 10.1016/s2666-6367(21)00242-6
216 - The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma
  • Jan 31, 2021
  • Transplantation and Cellular Therapy
  • Forat Lutfi + 17 more

216 - The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

  • Abstract
  • Cite Count Icon 1
  • 10.1182/blood-2020-141231
The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma
  • Nov 5, 2020
  • Blood
  • Forat Lutfi + 17 more

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

  • Research Article
  • Cite Count Icon 4
  • 10.4037/aacnacc2022936
Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations
  • Dec 15, 2022
  • AACN Advanced Critical Care
  • Kent A Owusu + 2 more

Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations

  • Research Article
  • Cite Count Icon 44
  • 10.1016/s1470-2045(21)00353-3
CAR T-cell therapy for solid tumours
  • Jul 1, 2021
  • The Lancet Oncology
  • The Lancet Oncology

CAR T-cell therapy for solid tumours

  • Abstract
  • Cite Count Icon 2
  • 10.1182/blood-2020-136756
Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
  • Nov 5, 2020
  • Blood
  • Neeraj Saini + 21 more

Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

  • Abstract
  • Cite Count Icon 38
  • 10.1182/blood-2023-181857
BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study
  • Nov 2, 2023
  • Blood
  • Susan Bal + 19 more

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

  • Research Article
  • 10.1182/blood-2025-3706
Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma
  • Nov 3, 2025
  • Blood
  • Rui Liu + 11 more

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

  • Research Article
  • 10.1182/blood-2024-201809
Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma
  • Nov 5, 2024
  • Blood
  • Jennifer J Huang + 18 more

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

  • Abstract
  • Cite Count Icon 8
  • 10.1182/blood-2022-162594
CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry
  • Nov 15, 2022
  • Blood
  • Gilles Crochet + 15 more

CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry

  • Research Article
  • Cite Count Icon 18
  • 10.1111/bjh.18339
Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.
  • Jun 28, 2022
  • British Journal of Haematology
  • Bhagirathbhai Dholaria + 9 more

Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.

  • Research Article
  • Cite Count Icon 2
  • 10.1182/blood-2024-202243
Demographic Characteristics, Incidence and Outcomes of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients Undergoing CAR T-Cell Therapy: An Analysis of the National Inpatient Sample (NIS) - 2021
  • Nov 5, 2024
  • Blood
  • Srinishant Rajarajan + 7 more

Demographic Characteristics, Incidence and Outcomes of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients Undergoing CAR T-Cell Therapy: An Analysis of the National Inpatient Sample (NIS) - 2021

  • Research Article
  • 10.1182/blood-2025-3722
Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study
  • Nov 3, 2025
  • Blood
  • Nicola Polverelli + 32 more

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

  • Abstract
  • 10.1182/blood-2022-162411
Efficacy and Safety of Intravenous Chimeric Antigen Receptor T-Cell Therapy in Adults with Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
  • Nov 15, 2022
  • Blood
  • Karan Srisurapanont + 2 more

Efficacy and Safety of Intravenous Chimeric Antigen Receptor T-Cell Therapy in Adults with Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis

Save Icon
Up Arrow
Open/Close
  • Ask R Discovery Star icon
  • Chat PDF Star icon

AI summaries and top papers from 250M+ research sources.

Search IconWhat is the difference between bacteria and viruses?
Open In New Tab Icon
Search IconWhat is the function of the immune system?
Open In New Tab Icon
Search IconCan diabetes be passed down from one generation to the next?
Open In New Tab Icon